What changed from existing technology?
This study shows that blocking a protein called XPO1 can help the immune system fight small cell lung cancer better by changing how certain immune cells behave.
This is the first study to demonstrate that XPO1 regulates immune suppression in SCLC by controlling TRIM21 and IRF3, which affects macrophage polarization and anti-PD-1 therapy response.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
t. Here, we analyse preclinical mouse tumor models and patient-derived SCLC samples and identify Exportin 1 (XPO1) as a regulator of immune suppression in SC
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding suggests that targeting XPO1 could be a potential strategy to improve the effectiveness of anti-PD-1 immunotherapy in small cell lung cancer patients.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.